| |
Patients
|
IIEF-5 Score
|
Strategies for Treating ED
|
Penile Morphology
|
| |
|
|
|
|
|
|
PDE-5 
|
|
|
Angle (degree)
|
Satisfaction
|
| Grouping |
No. |
Age |
Pre-op |
Post-op (1/2 year) |
Post-op (1 year) |
Post-op (2 years) |
Pre-op |
Post-op |
PI |
ICI |
Pre-op |
Post-op |
No. / % |
|
| Peyronie |
48 |
29-76 |
18.3±3.3 |
17.9±2.3 |
20.5±2.2 |
20.8±2.3 |
13 |
5 |
2 |
5 |
57.6±8.7 |
5.8±2.3 |
43/89.6 |
| CPD |
37 |
21-39 |
21.5±2.2 |
20.3±1.6 |
22.5±2.3 |
22.7±2.1 |
4 |
1 |
1 |
1 |
46.7±9.3 |
4.1±2.1 |
34/91.9 |
| Total |
85 |
56.8±9.2 |
19.7±2.8 |
18.9±2.9 |
21.3±2.2 |
21.6±2.2 |
17 |
6 |
3 |
6 |
|
|
77/90.6 |
P value |
|
<.001 |
<.001 |
<.001 |
<.01 |
<.01 |
<.01 |
|
|
|
|
|
|
| *CPD indicates congenital penile deviation; ED, erectile dysfunction; PDE-5
, phosphodiesterase-5 inhibitors; PI, penile implant; and ICI,
intracavernosal injection of the prostaglandin-E1. |
| Univariate comparisons were performed using the Wilcoxon signed rank
test as necessary for parameters with continuous values and Fisher's exact
test for those of discontinuous parameters. |
|